Molecular Approaches To Vaccine Development For Hepatitis C
Molecular Approaches To Vaccine Development For Hepatitis C
批准号:
7593663
负责人:
T. Jake Liang
金额:
$49.8万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AdjuvantAnimalsAntibodiesAntigensArchitectureArtsBindingCD8B1 geneCaliberCellsChronic HepatitisClinicalComplexCryoelectron MicroscopyCultured CellsDengue VirusDepthEngineeringEpitopesFlavivirusGenesGlycoproteinsHCV VaccineHealthHepatitis CHepatitis C virusHumanImmune responseImmunityImmunizationInfectionInsectaInterferon Type IILaboratoriesLymphocyteModalityModelingMolecularMolecular ConformationMonoclonal AntibodiesMusNegative StainingPan GenusPan troglodytesPapioPatternPeripheralPopulationPrimary carcinoma of the liver cellsPropertyProteinsRangeRecombinantsSerologicalSiteSourceStructural ProteinStructureSubunit VaccinesSystemT-LymphocyteT-Lymphocyte EpitopesTechnologyTreatment ProtocolsViralViral ProteinsViremiaVirionVirus AssemblyVirus-like particleWeekdensitydesigndimerfallsimmunogenicityimprovedinsightintrahepaticparticleplasmid DNAreconstructionresponsesizetissue culturevaccine developmentviral RNA
中文摘要
我们在昆虫细胞中开发了一种将HCV结构蛋白高效组装成HCV样颗粒(HCV- lps)的系统。这些非传染性的HCV样颗粒与从HCV感染者中分离出来的假定病毒粒子具有相似的形态、血清学和生物物理特性。与重组亚单位疫苗相比,hcv样颗粒的病毒蛋白可能以天然的病毒粒子样构象呈现,因此可能在引发保护性体液和细胞免疫反应方面优于重组亚单位疫苗。HCV-LP的体液和细胞免疫原性先前已在小鼠和狒狒模型中得到证实。
英文摘要
A system for efficient assembly of HCV structural proteins into HCV-like particles (HCV-LPs) in insect cells has been developed in our laboratory. These noninfectious HCV-like particles have similar morphologic, serologic and biophysical properties as the putative virions isolated from HCV infected humans. In contrast to recombinant subunit vaccines, the viral proteins of HCV-like particles may be presented in a native, virion-like conformation and may therefore be superior in eliciting a protective humoral and cellular immune response. The humoral and cellular immunogenicity of the HCV-LP had previously been demonstrated in the mouse and baboon models.
Recently, we demonstrated the immunogenicity and induction of protective immunity by HCV-LP in chimpanzees. Chimpanzees, two in each group, were immunized with HCV-LP or HCV-LP adjuvant ASO1B. After four immunizations over an eight-month period, all animals developed strong HCV-specific cellular immune response including IFN-gamma and IL-2, CD4 and CD8 T-cell and proliferative lymphocyte responses against core, E1 and E2. The chimpanzees in both groups were challenged with a 100 CID50 of HCV CG1B inoculum. Upon challenge with HCV, one chimpanzee developed transient viremia with low HCV RNA titers (10E3-4 copiesml) in the third and fourth weeks post-challenge. The three other chimpanzees became infected with higher levels of viremia (10E4-5 copiesml) but their viral levels became unquantifiable (< 1000 copiesml) 10 weeks post-challenge. After HCV challenge, all four chimpanzees demonstrated a significant increase in peripheral IFN-gamma T-cell and proliferative responses as well as the presence of intrahepatic T-cell response against the HCV structural proteins. These T-cell responses coincided with the fall in HCV RNA level. Previously, four nave chimpanzees were infected with the same HCV inoculum, and three developed persistent infection with viremia in the range of 10E5-6 copiesml. Our study suggests that HCV-LP immunization induces strong HCV-specific cellular immune responses and confers partial protection against HCV challenge in the chimpanzee model. In an effort to improve and broaden the immunogenicity of HCV-LP, we are engineering T cell epitopes from the nonstructural genes into the HCV-LP. In addition, we are combining The HCV-LP approach with other modalities of immunization, such as plasmid DNA, in a prime-boost regimen.
Understanding the structural features of HCV is crucial in designing immunogen that would induce protective immunity. The structural details of hepatitis C virus (HCV) have been elusive because of the lack of a robust tissue culture system for producing an adequate amount of virions from infectious sources for in-depth three-dimensional (3D) structural analysis. Using both negative-stain and cryo-electron microscopy (cryoEM), we show that HCV virions isolated from cell culture have a rather uniform size of 50 nm in diameter and that recombinantly expressed HCV-like particles (HCV-LPs) have similar morphologic, biophysical, and antigenic features. 3D reconstructions were obtained from HCV-LPs having the same size as the HCV virions in the presence and absence of monoclonal antibodies bound to the E1 glycoprotein. The 3D reconstruction of HCV-LP reveals a multilayered architecture, with smooth outer-layer densities arranged in a fishbone configuration. Reconstruction of the particles in complex with anti-E1 antibodies shows that sites of the E1 epitope are exposed and surround the 5-, 3-, and 2-fold axes. The binding pattern of the anti-E1 antibody and the fitting of the structure of the dengue virus E glycoprotein into our 3D reconstructions further suggest that the HCV-LP E1 and E2 proteins form a tetramer (or dimer of heterodimers) that corresponds morphologically and functionally to the flavivirus E homodimer. This first 3D structural analysis of HCV particles offers important insights into the elusive mechanisms of HCV assembly and maturation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nonalcoholic Steatohepatitis: Natural History, Pathogenesis and Therapy
-
批准号:7967807
-
项目类别:
-
资助金额:$48.34万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Studies of HCV Infection And HCV-Host interactions
-
批准号:8939616
-
项目类别:
-
资助金额:$88.38万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Molecular Mechanisms Of Hepatitis B Viral infection, Pathogenesis And Persistence
-
批准号:10697773
-
项目类别:
-
资助金额:$170.73万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Studies of HCV Infection, Vaccine Development and HCV-Host interactions
-
批准号:10697775
-
项目类别:
-
资助金额:$56.91万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Molecular Mechanisms Of Hepatitis B Viral Pathogenesis And Persistence
-
批准号:7734190
-
项目类别:
-
资助金额:$46.61万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Molecular Approaches To Vaccine Development For Hepatitis C
-
批准号:7734192
-
项目类别:
-
资助金额:$50.67万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Nonalcoholic Steatohepatitis: Natural History and Therapy
-
批准号:7734346
-
项目类别:
-
资助金额:$46.61万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Mechanisms of Therapy and Model Development in Viral Hepatitis and Liver Diseases
-
批准号:10248152
-
项目类别:
-
资助金额:$100.81万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Studies of HCV Infection And HCV-Host interactions
-
批准号:10000721
-
项目类别:
-
资助金额:$124.67万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Molecular Approaches To Antiviral Development For Viral Hepatitis and Other Viral Diseases
-
批准号:10919437
-
项目类别:
-
资助金额:$219.81万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Mechanisms of Interferon Action and Resistance in Hepatitis C Virus Infection
-
批准号:7593665
-
项目类别:
-
资助金额:$50.13万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Nonalcoholic Steatohepatitis: Natural History, Pathogenesis and Therapy
-
批准号:8148938
-
项目类别:
-
资助金额:$38.98万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Molecular Mechanisms Of Hepatitis B Viral Pathogenesis And Persistence
-
批准号:8553526
-
项目类别:
-
资助金额:$66.47万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Molecular Approaches To Vaccine Development For Hepatitis C
-
批准号:7967543
-
项目类别:
-
资助金额:$64.45万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Mechanisms of Interferon Action and Resistance in Hepatitis C Virus Infection
-
批准号:7734194
-
项目类别:
-
资助金额:$50.33万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Molecular Mechanisms Of Hepatitis B Viral Pathogenesis And Persistence
-
批准号:8939614
-
项目类别:
-
资助金额:$70.7万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Molecular Mechanisms Of Hepatitis B Viral Pathogenesis And Persistence
-
批准号:8148824
-
项目类别:
-
资助金额:$38.98万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
The Genetics of Disease Progression and Treatment Response in Hepatitis C
-
批准号:8148833
-
项目类别:
-
资助金额:$38.98万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Cell Culture And Animal Models of HCV Infection And HCV-Host interactions
-
批准号:8148826
-
项目类别:
-
资助金额:$51.97万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
Molecular Approaches To Vaccine Development For Hepatitis C
-
批准号:8148825
-
项目类别:
-
资助金额:$38.98万
-
财政年份:--
-
负责人:T. Jake Liang
-
依托单位:
海外基金